Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 49

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 49
---
 of the Merger.

| 27 |

<div align='center'>THE MERGER</div>

This section and the section titled “The Merger Agreement” in this proxy statement describe the material aspects of the Merger, including the Merger Agreement. While TELO believes that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should carefully read this entire proxy statement for a more complete understanding of the Merger and the Merger Agreement, including the Merger Agreement attached as Annex A, the valuation report of TELI Pharmaceuticals, Inc. attached as Annex B, the valuation report for Telomir Pharmaceuticals Inc. is attached as Annex C, and the fairness opinion for the Merger attached as Annex D and the Telomir-1 License Agreement is attached as Annex E to this proxy statement, and the other documents to which you are referred herein. See the section titled “Where You Can Find More Information” in this proxy statement.

Background of the Merger

On December 10, 2024, TELI was incorporated in the state of Delaware. At such point, TELI’s owners and executives had considered separately and independently listing its shares on the Nasdaq Stock Exchange in 2025.

In July 2025, several holders of shares of TELI spoke with Erez Aminov, CEO of TELO about the possibility of TELI becoming a wholly-owned subsidiary of TELO, and forgo its planned stand-alone public offering. These discussions focused on TELO’s interest in acquiring TELI. TELO believed that the acquisition of TELI, particularly due to expanding the global reach of Telomir-1, would enhance shareholder value. Given the overlapping relationships and common interests between TELO and MIRALOGX, conversations regarding the proposed Merger were frequent, direct, and collaborative. See “ Interests of the TELO Directors, Executive Officers and Affiliate Shareholders in the Merger” on page 34 of this proxy statement for additional details.

On September 20, 2025, TELO conducted an introductory call with Moore Financial Consulting Ltd. (“Moore”) regarding conducting valuations of TELO and TELI for purposes of determining the Exchange Ratio to be used in the Merger based on the relative valuations of TELO and TELI.

On September 21, 2025, TELO and Moore provided TELI with a list of diligence